Company intelligence / Profile preview
Angiocrine Bioscience
San Diego, California, United Statesangiocrinebioscience.com ↗
- Ownership
- Private
- Employees
- ~32
- Development stage
- Phase 3
01
Overview
Currently conducting a Phase 3 double-blind, randomized, placebo-controlled study (E-CELERATE) to evaluate the efficacy and safety of AB-205 plus standard of care versus placebo in adults with lymphoma undergoing high-dose therapy and autologous hematopoietic cell transplantation. Previous Phase 1/2 study showed AB-205 was well tolerated with only 9% incidence of early oral/GI SRRT compared to 41% in a contemporary observational study.
- Therapeutic areas
- GastroenterologyImmunologyOtherOncologyNeurology
- Modalities
- Engineered Cell TherapyGene TherapyStem Cell Therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Angiocrine Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angiocrine Bioscience.